Nautilus Biotechnology Announces Board Changes for 2025

Nautilus Biotechnolgy ( (NAUT) ) has shared an update.

Nautilus Biotechnology announced changes in its board of directors for the 2025 annual meeting, with Vijay Pande and Michael Altman stepping down, and Matthew McIlwain transitioning to a Class I director to maintain board balance. The company also reported its financial results for the fourth quarter and fiscal year 2024, highlighting a slight increase in operating expenses and a net loss compared to the previous year. Nautilus plans to launch its proteome analysis platform in late 2026 and has reduced its workforce by 16% to align resources with development goals, aiming to extend its cash runway through 2027.

More about Nautilus Biotechnolgy

Nautilus Biotechnology, Inc., headquartered in Seattle, Washington, is a life sciences company focused on developing a platform technology for single-molecule proteome analysis. The company’s mission is to transform proteomics by democratizing access to the proteome, facilitating advancements in human health and medicine.

YTD Price Performance: -15.38%

Average Trading Volume: 130,472

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $179.6M

See more insights into NAUT stock on TipRanks’ Stock Analysis page.